Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
about
Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.Biotransformation of the antiretroviral drug etravirine: metabolite identification, reaction phenotyping, and characterization of autoinduction of cytochrome P450-dependent metabolismPharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥3 to <12 Years.HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages.Clinical pharmacokinetics of antiretroviral drugs in older persons.Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infectionEtravirine Pharmacokinetics in HIV-Infected Pregnant Women.Caring for women living with HIV: gaps in the evidence.Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.Etravirine for the treatment of HIV/AIDS.Ageing with HIV: a multidisciplinary review.Assessment of Maraviroc Exposure-Response Relationship at 48 Weeks in Treatment-Experienced HIV-1-Infected Patients in the MOTIVATE Studies.Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.Pharmacokinetics of Darunavir/Ritonavir With Etravirine Both Twice Daily in Human Immunodeficiency Virus-Infected Adolescents and Young Adults.Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected PatientsAntiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.Steady-state pharmacokinetics of etravirine and lopinavir/ritonavir melt extrusion formulation, alone and in combination, in healthy HIV-negative volunteers.
P2860
Q33413634-1DB9EC1F-6EB0-45DF-A6CF-DCBE6756C67AQ35846917-534E5F8D-D328-4E86-AC80-C8B9D74559CFQ35867025-8F1C5C4D-4F90-4DD5-9D07-6ECBF80749A5Q35979557-94E99D63-02A2-4C82-A784-A3B0990B555AQ36368683-6F43DBE1-51E3-4F97-84D9-A203FD27E67DQ36905884-0995D221-3AC5-4A90-97D3-81CA4C822AB0Q37014157-33384B52-C81B-428E-8B2F-0EEBB53285EDQ37150339-97FD727B-F95B-47D0-A1CE-C994F6F13735Q37212049-430DCD1B-2783-4FEC-8DEA-62F298013925Q37722935-7963E391-1E5F-4BD2-A1F8-6BA10FB1C5F6Q38003399-596570A4-2252-434E-8541-D02FFE14FF13Q38096459-AFACF921-2A6E-4941-8392-928301F6B6C8Q38490362-2DDB608B-7695-4C5F-853B-AFBB8601E634Q39098454-3ED2CF45-5839-4236-A385-A81CC46799F0Q39353830-75EBF565-392A-4BE8-A4DD-A49542010845Q39831448-DDFCB8C1-254B-4971-8988-A871D19FF78FQ40722214-29B5711F-CA6B-49B7-9294-C50072ECB89CQ40784890-E5DF991E-417A-4421-95D8-6637C3A38384Q41494718-6A38B148-3D8B-42E5-93FB-0374546791EAQ41522665-A5208ABF-2F08-4680-8962-E724A1BA4B7CQ43418234-95E7A652-7494-420A-A4FF-37A43510977EQ44257576-BD3FBF16-DEBB-4924-A4E7-94FC5EBE336AQ45744226-F1845F3C-A0A3-4C42-8B48-F3923C0B10D0
P2860
Pharmacokinetics and pharmacodynamics of the non-nucleoside reverse-transcriptase inhibitor etravirine in treatment-experienced HIV-1-infected patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Pharmacokinetics and pharmacod ...... enced HIV-1-infected patients.
@en
Pharmacokinetics and pharmacod ...... enced HIV-1-infected patients.
@nl
type
label
Pharmacokinetics and pharmacod ...... enced HIV-1-infected patients.
@en
Pharmacokinetics and pharmacod ...... enced HIV-1-infected patients.
@nl
prefLabel
Pharmacokinetics and pharmacod ...... enced HIV-1-infected patients.
@en
Pharmacokinetics and pharmacod ...... enced HIV-1-infected patients.
@nl
P2093
P356
P1476
Pharmacokinetics and pharmacod ...... ienced HIV-1-infected patients
@en
P2093
B J Woodfall
G De Smedt
J Vingerhoets
M P Peeters
M Schöller-Gyüre
R M W Hoetelmans
P304
P356
10.1038/CLPT.2010.181
P407
P50
P577
2010-09-29T00:00:00Z